RECURSION PHARMACEUTICALS, INC. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 58/100
What the filing says
Christopher Gibson, founder, transitions from CEO to Advisor to CEO effective April 2026 under a 3-year agreement (through March 1, 2029) with COBRA health coverage for 12 months and continued vesting of prior equity awards; no cash salary specified in filing. Separately, David Mauro, M.D., Ph.D. (former Chief Medical Officer) enters short-term advisory agreement effective April 17, 2026, terminating May 29, 2026 (~6 weeks) to facilitate transition to new CMO Vicki Goodman, with continued vesting of prior equity awards. Najat Khan is now CEO. No dollar amounts for cash compensation disclosed for either advisor role.
Why this rating
Founder transition to advisory role is notable governance event but limited cash outlay disclosed. Both transitions appear orderly. Moderate significance relative to $2B market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.